FORM PTO 1449 (modified)	Atty. Docket No. X-16126	Serial No 10/597, 117	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Jeffrey Alan DODGE		
	Application Date US Nat'l Entry (if applicable) 7/12/2006	Group Art Unit 1625	

U.S. PA	TENT	DOCUMENTS			
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No. 1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Pages or Relevant Figures Appear
The same of the sa	***	US	***************************************		
	AB	US		***************************************	The state of the s

EODELON BATENTE DOCUMENTO

ixaminer Initials*	No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
ÇC/	BA	EP 0 761 659	03-12-1997	Eli Lilly and Co.	Page 1, line 3 – line 7; examples 2, 5,6	
	BB	WO 95/10513	04-20-1995	Pfizer, Inc. et al.	Table 2, p. 76, 2 nd structural formula; p. 77, 2 nd structural abstract; example 19	
	BC	EP 0 729 951	09-04-1996	Eli Lilly and Co.	The whole document	
	BD	EP 0 731 100	09-11-1996	Eli Lilly and Co.	The whole document	
	BE	WO 03/053977	07-03-2003	Ortho-McNeil Pharmaceutical, Inc	Claim 1	
	BF	EP 0 791 591	08-27-1997	Eli Lilly and Company	Examples p. 5, line 52 - line 54; claim 1	
CC/	BG	EP 0 761 669	03-12-1997	Eli Lilly and Company	Page 43; example 11b	

Examiner	(Calla Chana)	Date Considered	04/08/2009	
Signature	/Celia Chang/		04/00/2009	

*EXAMINER: Initial if reference occurdered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Japhones ranges citation designation standard optionals 2 See Toda Ondo of USBFO Phase I Demonstral or years upplying or MRFP PHA A.** Thate Collect for an order to dee Account by the two best code (VIFIO Shanded ST 2). **See Toda Ondo of Standard Collect for Standard Collect f

FORM PTO 1449 (modified)	Atty. Docket No.	Serial No
	X-16126	
INFORMATION DISCLOSURE CITATION	First Applicant	•
IN AN APPLICATION	Jeffrey Alan DODGE	
	Application Date	Group Art Unit
	US Nat'l Entry (if applicable)	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	т6
Initials*	No. 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	
/CC/	CA	Grese T. A., et al., "Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators", Journal of Organic Chemistry, Washington, USA, vol. 41, no. 8, pages 1272-1283, 1998.	
/CC/	СВ	Grese T. A., et al., "Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-Arylbenzothiophene core of raloxifene" Journal of Medicinal Chemistry, American Chemical Society, vol. 40, no. 2, pages 146-167, 1997.	

Examiner	iO-ll- Oh	Date Considered	0.4/00/0000		
Signature	/Celia Chang/		04/08/2009		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of					
this form with next communication to applicant					

Japhones ranges citation designation analises (specials, **) **See Kick Order of USPTO Phase to Demonstrate stress angle garge or MRTP PART A. Thater Office that cause the decreases the very level of the College of the Secretary of the Engress of the Secretary of the